PURASORB PLDL 7024 is a medical-grade poly(L-lactide-co-D,L-lactide) resin supplied for implantable and tissue-contacting devices. The copolymer carries a nominal L-lactide/DL-lactide molar ratio of 70:30 and a manufacturer-reported inherent viscosity midpoint of 0.24 dL/g in chloroform at 25°C at a concentration of 0.1 g/dL according to ISO 1628-1:2021. The DL-lactide units disrupt stereoregularity, so the resin is amorphous and exhibits a glass transition temperature near 55°C rather than a melting endotherm. This compositional position differentiates PLDL 7024 from semicrystalline poly(L-lactide) homopolymers, which retain crystallinity and higher mechanical strength, and from 50:50 poly(DL-lactide-co-glycolide) grades, which absorb water and degrade faster under neutral pH conditions. The product is intended for applications requiring low melt viscosity, organic-solvent solubility, and hydrolytic degradation without crystallinity-induced processing anisotropy. It is not supplied as a sterile or final-device material.

The batch certificate values listed above are supplier-controlled parameters and may vary by lot. Residual tin is controlled because stannous octoate is commonly used as the ring-opening catalyst; the certificate of analysis reports the batch-specific value. The designation as a medical device grade indicates manufacture under a quality system appropriate for devices, but final biological evaluation remains the responsibility of the finished-device manufacturer.

How Does the 70:30 L/DL-Lactide Copolymer Structure Control Degradation Rate?

The hydrolytic degradation of PLDL 7024 proceeds by bulk erosion rather than surface erosion. Ester bonds in the amorphous phase are accessible to water, and the low inherent viscosity reduces the number of chain entanglements per unit volume. Consequently, molecular weight decreases before substantial mass loss is observed. The 70:30 L/DL-lactide ratio introduces methyl side groups on each lactide repeat unit but excludes glycolic acid; this reduces water uptake relative to PLGA and slows the autocatalytic acidification that accelerates degradation in 50:50 PLGA. In contrast to semicrystalline PLLA, no crystalline lamellae delay water diffusion, so degradation is more uniform across the implant cross-section. Published data for this specific grade at 37°C in phosphate-buffered saline is limited, but the compositional trend is consistent with other amorphous lactide copolymers. Testing of device-specific mass loss and molecular weight retention should follow ASTM F1635-16 or an equivalent method selected for the implant geometry.

Because the DL-lactide comonomer suppresses crystallization, PLDL 7024 does not exhibit the annealing-induced density increase seen in poly(L-lactide). This removes one source of in vivo dimensional change but does not eliminate water uptake or plasticization. The relationship between degradation rate and device surface area is nonlinear; thin films and microparticles acidify more rapidly than dense monoliths because carboxylic acid degradation products diffuse over shorter length scales.

Because the glass transition is near 55°C, drying protocols for PLDL 7024 must remain below the onset of particle fusion. Vacuum drying at 40°C to 60°C for a minimum of 4 h is typical for low-molecular-weight amorphous lactide copolymers; the target moisture content is below 0.025% before melt processing. At relative humidity above 60%, granule moisture can exceed 0.5% rapidly, and hydrolysis during extrusion then reduces molecular weight and creates bubbles or filament surging. Positive-pressure nitrogen should be used during hopper loading and storage transfers. Direct heated trays above 65°C are avoided because particle agglomeration may occur even in the absence of moisture. Once the package is opened, the material should be used or redried, because low-molecular-weight amorphous polyesters absorb moisture faster than semicrystalline PLLA grades.

Extrusion and Injection Molding Boundaries on Medical Device Lines

On a 30 mm co-rotating twin-screw extruder with an L/D ratio of 40:1, PLDL 7024 exhibits low torque and melt pressure compared with higher-IV lactide copolymers. Barrel temperatures of 130°C to 170°C and a cooled feed throat are typical; die pressures below 20 bar may indicate feed instability or low melt viscosity rather than screw wear. For injection molding, the amorphous resin permits mold temperatures of 15°C to 30°C, which reduces cycle time but may increase weld-line visibility in thin-wall parts. Gate blush and nozzle drool occur when the melt temperature exceeds 175°C, especially with prolonged residence. Because the material is amorphous, shrinkage is isotropic and lower than that of semicrystalline PLLA, but ejection pins must be designed for a soft, low-modulus part.

Short shots and weld lines are observed in thin-wall parts when mold temperature falls below 15°C, because the melt freezes before filling. Clamp force requirements are lower than for high-viscosity PLLA; a 50-ton press is generally adequate for multi-cavity molds with shot weights below 5 g. Cavity pressure sensors are recommended because the low melt viscosity produces a rapid pressure drop after fill, making switchover timing critical. Screw recovery and plasticating capacity should be matched to the low melt viscosity, because excessive screw speed can generate shear heating and drive the melt above 180°C.

Residence time distribution is a critical processing boundary. At 170°C, random chain scission becomes measurable within 5 min to 10 min; purging with higher-viscosity PLA or rapid die removal is therefore required during line stops. Residual lactide can vaporize and condense on vent ports, causing vacuum-line fouling and cleanroom contamination. A vent vacuum of -0.08 MPa or deeper is typical for removing volatile monomer, but published data for this specific grade under production conditions is limited.

In solvent-based processing, PLDL 7024 dissolves in dichloromethane, chloroform, acetone, and ethyl acetate at solids loadings up to 20% w/v depending on molecular weight and temperature. Filtration through a 0.22 µm membrane removes gel bodies before film casting or spray coating. Residual solvent removal is performed under vacuum at 35°C to 45°C to avoid foaming above the glass transition. The low solution viscosity allows spray coating of stents and microsphere production, but solvent choice must comply with ICH Q3C residual solvent limits when the device is a drug-delivery product. For microspheres, an oil-in-water emulsion with polyvinyl alcohol as stabilizer is often used; solvent evaporation at 35°C reduces residual dichloromethane. Acidic degradation products may lower local pH in microparticle formulations, so buffering agents such as calcium carbonate or magnesium hydroxide are often required for acid-labile peptides.

When Gamma Sterilization Is Required Instead of Ethylene Oxide

Gamma irradiation at 25 kGy to 40 kGy may be used for terminally sterilized resorbable devices, but the low molecular weight of PLDL 7024 makes it susceptible to radiation-induced chain scission. At 25 kGy, a measurable decrease in inherent viscosity is expected; the magnitude depends on oxygen concentration, temperature, and packaging atmosphere. Ethylene oxide is often selected for porous or drug-loaded implants because processing occurs below 55°C, but residual ethylene oxide and ethylene chlorohydrin must meet ISO 10993-7:2008 limits. Steam sterilization is incompatible because the polymer hydrolyzes and deforms above the glass transition. Dry heat sterilization is generally unsuitable due to thermal degradation. After gamma irradiation, molecular weight may decrease further, so terminal sterilization must be validated after final packaging. Aeration after ethylene oxide exposure at 45°C for 24 h is a common starting condition, but release requires batch-specific residue data.

Manufacture of PURASORB PLDL 7024 is supported by a quality system certified to ISO 13485:2016. The grade is not a sterilized final device; biological evaluation of the finished device should follow ISO 10993-1:2018, including tests for cytotoxicity, sensitization, irritation, and implantation as indicated by device nature and duration of contact. Chemical characterization should follow ISO 10993-18:2020. Terminal packaging should provide a validated microbial barrier and seal integrity under ISO 11607-1:2019 and ISO 11607-2:2019. The material is not approved by FDA or notified bodies as a standalone drug substance; regulatory responsibility resides with the finished-device manufacturer.

Thermal Degradation Pathways and Residence Time Limits in Melt Processing

At temperatures above 180°C, random chain scission and unzipping to lactide monomer occur simultaneously. The unzipping reaction liberates lactide vapors, which condense on vent ports and die faces. This volatile condensate can block vacuum lines and contaminate cleanrooms. Color shifts from white to pale yellow indicate degradation; measurable yellowing occurs more rapidly under oxygen than under nitrogen. The degradation products are acidic, and repeated processing of reground PLDL 7024 can accelerate additional chain scission. A maximum regrind fraction of 20% is used in many medical device processes, but the acceptable fraction must be validated for the specific implant because the low initial molecular weight leaves limited margin for hydrolysis.

Moisture-induced hydrolysis is a more common failure mode than thermal degradation. During extrusion, moisture levels above 0.025% produce visible bubbles, melt-pressure fluctuation, and reduced inherent viscosity. On-line melt pressure monitoring may show a downward drift as chain scission occurs. Blown film and monofilament lines show pronounced diameter variation when moisture is not controlled. The polymer should therefore be dried immediately before processing, and hopper residence time under ambient air should be minimized.

Compared with higher-IV versions of the 70:30 L/DL-lactide copolymer, PLDL 7024 has lower melt and solution viscosity, faster mass loss, and reduced mechanical strength. Compared with semicrystalline PLLA, it eliminates quench-induced crystallization warpage and shortens degradation time. Compared with 50:50 PLGA, it swells less and degrades more slowly in neutral pH buffers. These differences direct material selection toward low-viscosity processing and short-to-intermediate degradation profiles. The resin is not suitable for self-reinforced absorbable implants or load-bearing screws; published data for this specific configuration in load-bearing orthopaedic applications is limited. Amine-based additives and strongly alkaline fillers should be avoided because they catalyze ester hydrolysis and reduce shelf life. Storage in sealed bags below -20°C is recommended; before opening, the package should reach room temperature to avoid moisture condensation.